Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.
Number of employees : 617 people.
|USD (in Million)||%||USD (in Million)||%|
|Research and Development Service||39.50||4.6%||49.97||5.2%|| +26.49%|
|USD (in Million)||%|
|Vote ||Quantity||Free-Float||Company-owned shares||Total Float
|The Vanguard Group, Inc. ||28,317,428||
|Renaissance Technologies LLC ||23,006,910||
|Capital Research & Management Co. (Global Investors) ||22,565,030||
|T. Rowe Price Associates, Inc. (Investment Management) ||13,464,133||
|Meditor Capital Management Ltd. ||12,841,798||
|BlackRock Fund Advisors ||10,312,056||
|Farallon Capital Management LLC ||10,250,000||
|Matrix Capital Management Co. LP ||10,000,000||
|SSgA Funds Management, Inc. ||9,672,153||
|AJO LP ||7,636,882||
|Company contact information|
1851 Harbor Bay
Alameda, CA 94502
Phone : +1.650.837.7000
Fax : +1.650.837.8300
Web : http://www.exelixis.com
The most promising biotech firm in the US?
Sector Bio Therapeutic Drugs
Connections : Exelixis, Inc.